Who
Helen Sabzevari
President and CEO
Company insider
Files Form 4 as: President and CEO, Precigen; Director, Kinnate Biopharma.
In numbers
- Trades disclosed
- 140
- Buys
- 1
- Sells
- 25
- Bought
- $40K
- Sold
- $9.5M
- Companies
- 2
- Companies where not an officer
- 1
- First trade
- 2 Jan 2018
- Last trade
- 23 Aug 2026
- Last filed
- 25 Aug 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 23 Aug 2026filed 25 Aug 2026 | PGEN PrecigenBiotechnology | SEC FORM 4 Code M | —20,833 | filing |
| 23 Aug 2026filed 25 Aug 2026 | PGEN PrecigenBiotechnology | SEC FORM 4 Code F | $73K10,184 at $7.20 | filing |
| 23 Aug 2026filed 25 Aug 2026 | PGEN Precigenoption or derivative · Biotechnology | SEC FORM 4 Code M | —20,833 at $0.00 | filing |
| 23 Aug 2026filed 25 Aug 2026 | PGEN Precigenoption or derivative · Biotechnology | SEC FORM 4 Code M | —20,833 at $0.00 | filing |
| 23 Aug 2026filed 25 Aug 2026 | PGEN PrecigenBiotechnology | SEC FORM 4 Code M | —20,833 | filing |
| 23 Aug 2026filed 25 Aug 2026 | PGEN PrecigenBiotechnology | SEC FORM 4 Code F | $73K10,184 at $7.20 | filing |
| 29 Jun 2026filed 1 Jul 2026 | PGEN PrecigenBiotechnology | SEC FORM 4 Code M | $808K346,836 at $2.33 | filing |
| 29 Jun 2026filed 1 Jul 2026 | PGEN PrecigenBiotechnology | SEC FORM 4 Sold | $2.0M346,836 at $5.89 | filing |
| 29 Jun 2026filed 1 Jul 2026 | PGEN Precigenoption or derivative · Biotechnology | SEC FORM 4 Code M | —346,836 at $0.00 | filing |
| 29 Jun 2026filed 1 Jul 2026 | PGEN Precigenoption or derivative · Biotechnology | SEC FORM 4 Code M | —346,836 at $0.00 | filing |
| 29 Jun 2026filed 1 Jul 2026 | PGEN PrecigenBiotechnology | SEC FORM 4 Code M | $808K346,836 at $2.33 | filing |
| 29 Jun 2026filed 1 Jul 2026 | PGEN PrecigenBiotechnology | SEC FORM 4 Sold | $2.0M346,836 at $5.89 | filing |
| 28 May 2026filed 1 Jun 2026 | PGEN PrecigenBiotechnology | SEC FORM 4 Sold | $520K119,250 at $4.36 | filing |
| 28 May 2026filed 1 Jun 2026 | PGEN PrecigenBiotechnology | SEC FORM 4 Sold | $520K119,250 at $4.36 | filing |
| 23 May 2026filed 27 May 2026 | PGEN PrecigenBiotechnology | SEC FORM 4 Code M | —250,000 | filing |
| 23 May 2026filed 27 May 2026 | PGEN Precigenoption or derivative · Biotechnology | SEC FORM 4 Code M | —250,000 at $0.00 | filing |
| 23 May 2026filed 27 May 2026 | PGEN Precigenoption or derivative · Biotechnology | SEC FORM 4 Code M | —250,000 at $0.00 | filing |
| 23 May 2026filed 27 May 2026 | PGEN PrecigenBiotechnology | SEC FORM 4 Code M | —250,000 | filing |
| 20 Apr 2026filed 22 Apr 2026 | PGEN Precigenoption or derivative · Biotechnology | SEC FORM 4 Code A | —1,366,000 at $0.00 | filing |
| 20 Apr 2026filed 22 Apr 2026 | PGEN Precigenoption or derivative · Biotechnology | SEC FORM 4 Code A | —410,000 at $0.00 | filing |
News
No headline names them, or the companies they trade most, lately.